FLT1 and glioblastoma: To dissect the molecular mechanisms of these new EZH2 inhibitors, their efficacy in mitigating the GBM malignant phenotype has been determined through the reduction of VEGFR1/VEGF expression, reversion of the EMT process, inhibition of invasive phenotype, and decrease of inflammatory cytokines levels.